Does the media prefer PLSE or KIDS?

In the previous week, Pulse Biosciences had 3 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Pulse Biosciences and 3 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.63 beat Pulse Biosciences' score of 0.31 indicating that OrthoPediatrics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OrthoPediatrics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRCT or KIDS?

In the previous week, PROCEPT BioRobotics had 10 more articles in the media than OrthoPediatrics. MarketBeat recorded 13 mentions for PROCEPT BioRobotics and 3 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.63 beat PROCEPT BioRobotics' score of 0.23 indicating that OrthoPediatrics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral OrthoPediatrics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, KIDS or CDRE?

Cadre has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OrthoPediatrics $243.30M 1.88 -$39.65M -$1.68 N/A Cadre $635.63M 2.06 $44.14M $0.89 34.31

Does the media refer more to KIDS or CDRE?

In the previous week, OrthoPediatrics had 1 more articles in the media than Cadre. MarketBeat recorded 3 mentions for OrthoPediatrics and 2 mentions for Cadre. Cadre's average media sentiment score of 1.38 beat OrthoPediatrics' score of 0.63 indicating that Cadre is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OrthoPediatrics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cadre 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TNDM or KIDS?

In the previous week, Tandem Diabetes Care had 3 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Tandem Diabetes Care and 3 mentions for OrthoPediatrics. Tandem Diabetes Care's average media sentiment score of 0.71 beat OrthoPediatrics' score of 0.63 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OrthoPediatrics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OrthoPediatrics (KIDS) Competitors

$17.82 -0.01 (-0.06%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$17.84 +0.02 (+0.11%)

As of 06/12/2026 05:35 PM Eastern

Compare

KIDS vs. PLSE, PRCT, CDRE, TNDM, and BLFS

Should you buy OrthoPediatrics stock or one of its competitors? MarketBeat compares OrthoPediatrics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OrthoPediatrics include Pulse Biosciences (PLSE), PROCEPT BioRobotics (PRCT), Cadre (CDRE), Tandem Diabetes Care (TNDM), and BioLife Solutions (BLFS). These companies are all part of the "medical equipment" industry.

How does OrthoPediatrics compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Pulse Biosciences has a net margin of 0.00% compared to OrthoPediatrics' net margin of -16.31%. OrthoPediatrics' return on equity of -7.01% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	N/A	-86.67%	-73.61%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

Pulse Biosciences currently has a consensus price target of $30.67, indicating a potential upside of 25.84%. OrthoPediatrics has a consensus price target of $24.44, indicating a potential upside of 37.17%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts plainly believe OrthoPediatrics is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Pulse Biosciences had 3 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Pulse Biosciences and 3 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.63 beat Pulse Biosciences' score of 0.31 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OrthoPediatrics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

76.9% of Pulse Biosciences shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Pulse Biosciences has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

OrthoPediatrics has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$751K	2,245.87	-$72.78M	-$1.10	N/A
OrthoPediatrics	$243.30M	1.88	-$39.65M	-$1.68	N/A

Summary

OrthoPediatrics beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

How does OrthoPediatrics compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

OrthoPediatrics has a net margin of -16.31% compared to PROCEPT BioRobotics' net margin of -31.82%. OrthoPediatrics' return on equity of -7.01% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

OrthoPediatrics has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	4.75	-$95.57M	-$1.82	N/A
OrthoPediatrics	$243.30M	1.88	-$39.65M	-$1.68	N/A

In the previous week, PROCEPT BioRobotics had 10 more articles in the media than OrthoPediatrics. MarketBeat recorded 13 mentions for PROCEPT BioRobotics and 3 mentions for OrthoPediatrics. OrthoPediatrics' average media sentiment score of 0.63 beat PROCEPT BioRobotics' score of 0.23 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
OrthoPediatrics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PROCEPT BioRobotics has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

89.5% of PROCEPT BioRobotics shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 6.6% of PROCEPT BioRobotics shares are held by insiders. Comparatively, 32.7% of OrthoPediatrics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PROCEPT BioRobotics presently has a consensus target price of $41.36, suggesting a potential upside of 60.95%. OrthoPediatrics has a consensus target price of $24.44, suggesting a potential upside of 37.17%. Given PROCEPT BioRobotics' higher possible upside, equities analysts plainly believe PROCEPT BioRobotics is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.36
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

OrthoPediatrics beats PROCEPT BioRobotics on 12 of the 17 factors compared between the two stocks.

How does OrthoPediatrics compare to Cadre?

OrthoPediatrics (NASDAQ:KIDS) and Cadre (NYSE:CDRE) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Cadre has a net margin of 5.80% compared to OrthoPediatrics' net margin of -16.31%. Cadre's return on equity of 12.39% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-16.31%	-7.01%	-4.86%
Cadre	5.80%	12.39%	5.08%

Cadre has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$243.30M	1.88	-$39.65M	-$1.68	N/A
Cadre	$635.63M	2.06	$44.14M	$0.89	34.31

OrthoPediatrics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Cadre has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

OrthoPediatrics presently has a consensus price target of $24.44, suggesting a potential upside of 37.17%. Cadre has a consensus price target of $39.75, suggesting a potential upside of 30.16%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, equities analysts plainly believe OrthoPediatrics is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 32.7% of OrthoPediatrics shares are owned by company insiders. Comparatively, 30.1% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, OrthoPediatrics had 1 more articles in the media than Cadre. MarketBeat recorded 3 mentions for OrthoPediatrics and 2 mentions for Cadre. Cadre's average media sentiment score of 1.38 beat OrthoPediatrics' score of 0.63 indicating that Cadre is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OrthoPediatrics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cadre	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cadre beats OrthoPediatrics on 10 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

69.1% of OrthoPediatrics shares are owned by institutional investors. 2.1% of Tandem Diabetes Care shares are owned by insiders. Comparatively, 32.7% of OrthoPediatrics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tandem Diabetes Care currently has a consensus target price of $29.84, suggesting a potential upside of 79.77%. OrthoPediatrics has a consensus target price of $24.44, suggesting a potential upside of 37.17%. Given Tandem Diabetes Care's higher probable upside, equities analysts clearly believe Tandem Diabetes Care is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.48
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

OrthoPediatrics has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	1.12	-$204.71M	-$1.40	N/A
OrthoPediatrics	$243.30M	1.88	-$39.65M	-$1.68	N/A

Tandem Diabetes Care has a net margin of -9.20% compared to OrthoPediatrics' net margin of -16.31%. OrthoPediatrics' return on equity of -7.01% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

Tandem Diabetes Care has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

In the previous week, Tandem Diabetes Care had 3 more articles in the media than OrthoPediatrics. MarketBeat recorded 6 mentions for Tandem Diabetes Care and 3 mentions for OrthoPediatrics. Tandem Diabetes Care's average media sentiment score of 0.71 beat OrthoPediatrics' score of 0.63 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OrthoPediatrics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tandem Diabetes Care and OrthoPediatrics tied by winning 8 of the 16 factors compared between the two stocks.

How does OrthoPediatrics compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

BioLife Solutions has higher earnings, but lower revenue than OrthoPediatrics. BioLife Solutions is trading at a lower price-to-earnings ratio than OrthoPediatrics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	13.25	-$4.59M	-$0.08	N/A
OrthoPediatrics	$243.30M	1.88	-$39.65M	-$1.68	N/A

BioLife Solutions has a net margin of -2.80% compared to OrthoPediatrics' net margin of -16.31%. BioLife Solutions' return on equity of 1.81% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BioLife Solutions has a beta of 2, meaning that its share price is 100% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market.

BioLife Solutions presently has a consensus price target of $32.00, suggesting a potential upside of 22.61%. OrthoPediatrics has a consensus price target of $24.44, suggesting a potential upside of 37.17%. Given OrthoPediatrics' stronger consensus rating and higher possible upside, analysts plainly believe OrthoPediatrics is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, OrthoPediatrics had 2 more articles in the media than BioLife Solutions. MarketBeat recorded 3 mentions for OrthoPediatrics and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.88 beat OrthoPediatrics' score of 0.63 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
BioLife Solutions	Very Positive
OrthoPediatrics	Positive

Summary

BioLife Solutions beats OrthoPediatrics on 9 of the 17 factors compared between the two stocks.

Get OrthoPediatrics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KIDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KIDS vs. The Competition

Export

Metric	OrthoPediatrics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$457.71M	$7.18B	$6.72B	$12.07B
Dividend Yield	N/A	1.21%	2.67%	5.67%
P/E Ratio	-10.61	47.88	24.24	24.42
Price / Sales	1.88	42.96	481.04	86.26
Price / Cash	107.16	25.07	43.54	55.64
Price / Book	1.29	6.85	10.65	6.80
Net Income	-$39.65M	$159.22M	$3.57B	$338.00M
7 Day Performance	-2.73%	-1.27%	0.84%	2.68%
1 Month Performance	-0.45%	3.59%	-0.34%	1.56%
1 Year Performance	-15.78%	1.23%	25.40%	30.59%

OrthoPediatrics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KIDS OrthoPediatrics	3.0075 of 5 stars	$17.82 -0.1%	$24.44 +37.2%	-15.8%	$457.71M	$243.30M	N/A	200
PLSE Pulse Biosciences	3.3986 of 5 stars	$24.28 -1.6%	$30.00 +23.6%	+54.5%	$1.71B	$350K	N/A	140
PRCT PROCEPT BioRobotics	2.7983 of 5 stars	$26.76 -3.9%	$41.45 +54.9%	-57.6%	$1.59B	$308.05M	N/A	430	News Coverage Analyst Downgrade
CDRE Cadre	4.733 of 5 stars	$30.23 -1.3%	$39.75 +31.5%	-11.4%	$1.31B	$610.31M	33.97	2,533
TNDM Tandem Diabetes Care	2.4587 of 5 stars	$18.60 -2.7%	$29.84 +60.4%	-20.0%	$1.31B	$1.01B	N/A	2,500	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KIDS) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OrthoPediatrics (KIDS) Competitors

KIDS vs. PLSE, PRCT, CDRE, TNDM, and BLFS

How does OrthoPediatrics compare to Pulse Biosciences?

Summary

How does OrthoPediatrics compare to PROCEPT BioRobotics?

Summary

How does OrthoPediatrics compare to Cadre?

Summary

How does OrthoPediatrics compare to Tandem Diabetes Care?

Summary

How does OrthoPediatrics compare to BioLife Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KIDS vs. The Competition

OrthoPediatrics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OrthoPediatrics (KIDS) Competitors

KIDS vs. PLSE, PRCT, CDRE, TNDM, and BLFS

How does OrthoPediatrics compare to Pulse Biosciences?

Is PLSE or KIDS more profitable?

Do analysts prefer PLSE or KIDS?

Does the media prefer PLSE or KIDS?

Do insiders & institutionals hold more shares of PLSE or KIDS?

Which has more volatility and risk, PLSE or KIDS?

Which has preferable valuation and earnings, PLSE or KIDS?

Summary

How does OrthoPediatrics compare to PROCEPT BioRobotics?

Is PRCT or KIDS more profitable?

Which has stronger earnings and valuation, PRCT or KIDS?

Does the media refer more to PRCT or KIDS?

Which has more risk and volatility, PRCT or KIDS?

Do institutionals and insiders hold more shares of PRCT or KIDS?

Do analysts rate PRCT or KIDS?

Summary

How does OrthoPediatrics compare to Cadre?

Is KIDS or CDRE more profitable?

Which has stronger valuation & earnings, KIDS or CDRE?

Which has more risk and volatility, KIDS or CDRE?

Do analysts prefer KIDS or CDRE?

Do institutionals & insiders hold more shares of KIDS or CDRE?

Does the media refer more to KIDS or CDRE?

Summary

How does OrthoPediatrics compare to Tandem Diabetes Care?

Do institutionals and insiders hold more shares of TNDM or KIDS?

Do analysts prefer TNDM or KIDS?

Which has better earnings and valuation, TNDM or KIDS?

Is TNDM or KIDS more profitable?

Which has more volatility and risk, TNDM or KIDS?

Does the media refer more to TNDM or KIDS?

Summary

How does OrthoPediatrics compare to BioLife Solutions?

Which has higher valuation and earnings, BLFS or KIDS?

Is BLFS or KIDS more profitable?

Do insiders and institutionals hold more shares of BLFS or KIDS?

Which has more volatility & risk, BLFS or KIDS?

Do analysts prefer BLFS or KIDS?

Does the media refer more to BLFS or KIDS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KIDS vs. The Competition

OrthoPediatrics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools